Forty-four patients with EGFR mutant NSCLC who had received osimertinib and had a median of four prior lines of therapy obtained an ORR of 39% (with complete responses in 2% of the patients) and an mPFS of 8.2 months. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.